Azithromycin is effective for the remission of cyclosporine A-induced gingival overgrowth (CIGO) in persons who have undergone renal transplant. To explain its mechanism in alleviating the clinical symptoms of these indivduals, we examined the effect of azithromycin on cell proliferation and collagen turnover modified by cyclosporin A in human gingival fibroblasts from healthy persons and from persons who had undergone renal transplant. Cyclosporin A-induced proliferation of renal transplant fibroblasts and normal fibroblasts was inhibited by azithromycin. Azithromycin elevated the reduced metalloproteinase (MMP)-1 and MMP-2 activities in cyclosporine A-treated renal transplant fibroblasts and normal fibroblasts. In cyclosporine A-treated renal transplant fibroblasts, azithromycin blocked the accumulation of total collagen in culture media and the increase in type I collagen mRNA level, but recovered the reduced MMP-2 mRNA level to the control. These results suggest that azithromycin may improve CIGO by blocking cyclosporine A-induced cell proliferation and collagen synthesis, and by activating MMP-2 in gingival fibroblasts of persons with cyclosporine A-induced gingival overgrowth.
Get full access to this article
View all access options for this article.
References
1.
Aimes RT, Quigley JP -1995-. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem270:5872–5876.
2.
Aimetti M, Romano F, DeBernardi C -2005-. Effectiveness of periodontal therapy on the severity of cyclosporin A-induced gingival overgrowth. J Clin Periodont32:846–850.
3.
Bader G, Lejeune S, Messner M -1998-. Reduction of cyclosporin-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. J Periodontol69:729–732; erratum in J Periodontol 69:1181, 1998.
4.
Bartold PM -1989-. Regulation of human gingival fibroblast growth and synthetic activity by cyclosporin-A in vitro. J Periodontal Res24:314–321.
5.
Bolzani G, Della Coletta R, Martelli Junior H, de Almeida OP, Graner E -2000-. Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. J Periodontal Res35:51–58.
6.
Bonnaure-Mallet M, Tricot-Doleux S, Godeau GJ -1995-. Changes in extracellular matrix macromolecules in human gingival after treatment with drugs inducing gingival overgrowth. Arch Oral Biol40:393–400.
7.
Citterio F, Di Pinto A, Borzi MT, Scata MC, Foco M, Pozzetto U, et al. -2001-. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc33:2134–2135.
8.
Cotrim P, de Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD -2002-. Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor -TGF--beta1 autocrine stimulation. J Periodontol73:1313–1322.
9.
Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A -1998-. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res58:3743–3750.
10.
Emonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM -1992-. Tumor cell surface-associated binding site for the M-r- 72,000 type IV collagenase. Cancer Res52:5845–5848.
11.
Gagliano N, Moscheni C, Dellavia C, Torri C, Stabellini G, Ferrario VF, et al. -2004-. Effect of cyclosporin A on human gingival fibroblast collagen turnover in relation to the development of gingival overgrowth: an in vitro study. Biomed Pharmacother58:231–238.
12.
Gomez E, Sanchez-Nunez M, Sanchez JE, Corte C, Aguado S, Portal C, et al. -1997-. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant12:2694–2697.
13.
Hyland PL, Traynor PS, Myrillas TT, Marley JJ, Linden GJ, Winter P, et al. -2003-. The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontol74:437–445.
14.
James JA, Boomer S, Maxwell AP, Hull PS, Short CD, Campbell BA, et al. -2000-. Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus. J Clin Periodontol27:144–148.
15.
Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, et al. -2000-. Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol182:351–358.
16.
Kato T, Okahashi N, Kawai S, Kato T, Inaba H, Morisaki I, et al. -2005-. Impaired degradation of matrix collagen in human gingival fibroblasts by the antiepileptic drug phenytoin. J Periodontol76:941–950.
17.
Kubota T, Matsuki Y, Nomura T, Hara K -1997-. In situ hybridization study on tissue inhibitors of metalloproteinases -TIMPs- mRNA-expressing cells in human inflamed gingival tissue. J Periodontal Res32:467–472.
18.
Kwun WH, Suh BY, Kwun K B -2003-. Effect of azithromycin in the treartment of cyclosporin-induced gingival hyperplasia in renal transplant recipients. Transplant Proc35:311–312.
19.
Nares S, Ng MC, Dill RE, Park B, Cutler CW, Iacopino AM -1996-. Cyclosporin A upregulates platelet-derived growth factor B chain in human hyperplastic gingiva. J Periodontol67:271–270.
20.
Noh HS, Chung WY, Choi SH, Cho KS, Park KK -2003-. The effect of azithromycin on the cyclosporin A-induced gingival fibroblast overgrowth. J Kor Acad Periodontol33:643–649.
21.
Paik JW, Kim CS, Cho KS, Chai JK, Kim CK, Choi SH -2004-. Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. J Periodontol75:380–387.
22.
Pernu HE, Pernu LM, Huttunen KR, Nieminen PA, Knuuttila ML -1992-. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontol63:548–553.
23.
Schincaglia GP, Forniti F, Cavallini R, Piva R, Calura G, del Senno L -1992-. Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med21:181–185.
24.
Seymour RA, Jacobs DJ -1992-. Cyclosporin A and the gingival tissues. J Clin Periodontol19:1–11.
25.
Seymour RA, Thomason JM, Ellis JS -1996-. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol23:165–175.
26.
Silva HC, Coletta RD, Jorge J, Bolzani G, de Almeida OP, Graner E -2001-. The effect of cyclosporin A on the activity of matrix metalloproteinase during the healing of rat molar extraction wounds. Arch Oral Biol46:875–879.
27.
Sugano N, Ito K, Murai S -1998-. Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. J Periodontal Res33:448–452.
28.
Tokgoz B, Sari HI, Yildiz O, Aslan S, Sipahioglu M, Okten T, et al. -2004-. Effects of azithromycin on cyclosporin-induced gingival hyperplasia in renal transplant patients. Transplant Proc36:2699–2702.
29.
Tuter G, Serdar MA, Yalim M, Gurhan IS, Balos K -2002-. Evaluation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 levels in gingival fibroblasts of cyclosporin A-treated patients. J Periodontol73:1273–1278.
30.
Tyldesley WR, Rotter E -1984-. Gingival hyperplasia induced by cyclosporin A. Br Dent J157:305–309.
31.
Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR -1983-. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Sur Oral Med Oral Pathol55:274–278.
32.
Yamada H, Nishimura F, Naruishi K, Chou HH, Takashiba S, Albright GM, et al. -2000-. Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol71:955–960.
33.
Yamaguchi M, Naruishi K, Yamada-Naruishi H, Omori K, Nishimura F, Takashiba S -2004-. Long-term cyclosporin A exposure suppresses cathepsin-B and –L activity in gingival fibroblasts. J Periodontal Res39:320–326.
